OpenLB
Open Library of Bioscience
Advanced Search

Journal

Publication Year

1 year 3 years 5 years 10 years
2021 - 2032
202120222023
202420252026
202720282029
203020312032
2021 - 2032
202120222023
202420252026
202720282029
203020312032

Publication Type

Associated Data

Found 116 results

Filters: apilimod

Drug evaluation: apilimod, an oral IL-12/IL-23 inhibitor for the treatment of autoimmune diseases and common variable immunodeficiency.
Andreas Billich
IDrugs. Jan, 2007.10(1):53-9 Print
Source:PubMed
PMID: 17187316 doi:
Brief report: a phase IIa, randomized, double-blind, placebo-controlled trial of apilimod mesylate, an interleukin-12/interleukin-23 inhibitor, in patients with rheumatoid arthritis.
Sarah Krausz, Maria J H Boumans, Danielle M Gerlag, Joelle Lufkin, Arno W R van Kuijk, Alian Bakker, Maarten de Boer, Beatrijs M Lodde, Kris A Reedquist, Eric W Jacobson, Michael O'Meara, Paul P Tak
Arthritis Rheum. Jun, 2012.64(6):1750-5 Print-Electronic
Source:PubMed
PMID: 22170479 doi:10.1002/art.34339
Apilimod dimesylate in C9orf72 amyotrophic lateral sclerosis: a randomized phase 2a clinical trial.
Suma Babu, Katharine A Nicholson, Jeffrey D Rothstein, Andrea Swenson, Paul J Sampognaro, Pravin Pant, Eric A Macklin, Susan Spruill, Sabrina Paganoni, Tania F Gendron, Mercedes Prudencio, Leonard Petrucelli, Darrell Nix, Sean Landrette, Esther Nkrumah, Keith Fandrick, Joan Edwards, Peter R Young
Brain. Sep 03, 2024.147(9):2998-3008 Print
Source:PubMed
PMID: 38606777 doi:10.1093/brain/awae109
Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease.
Bruce E Sands, Eric W Jacobson, Thomas Sylwestrowicz, Ziad Younes, Gerald Dryden, Richard Fedorak, Susan Greenbloom
Inflamm Bowel Dis. Jul, 2010.16(7):1209-18 Print
Source:PubMed
PMID: 19918967 doi:10.1002/ibd.21159
Apilimod activates the NLRP3 inflammasome through lysosome-mediated mitochondrial damage.
Yingting Hou, Hongbin He, Ming Ma, Rongbin Zhou
Front Immunol. 2023.14:1128700 Electronic-eCollection
Source:PubMed
PMID: 37359517 doi:10.3389/fimmu.2023.1128700
B-cell non-Hodgkin lymphoma: Selective vulnerability to PIKFYVE inhibition.
Sophia Gayle, Sean Landrette, Neil Beeharry, Chris Conrad, Marylens Hernandez, Paul Beckett, Shawn M Ferguson, Tian Xu, Jonathan Rothberg, Henri Lichenstein
Autophagy. Jun 03, 2017.13(6):1082-1083 Print-Electronic
Source:PubMed
PMID: 28350209 doi:10.1080/15548627.2017.1304871
Apilimod alters TGFβ signaling pathway and prevents cardiac fibrotic remodeling.
Mathieu Cinato, Laurie Guitou, Amira Saidi, Andrei Timotin, Erwan Sperazza, Thibaut Duparc, Sergey N Zolov, Sai Srinivas Panapakkam Giridharan, Lois S Weisman, Laurent O Martinez, Jerome Roncalli, Oksana Kunduzova, Helene Tronchere, Frederic Boal
Theranostics. 2021.11(13):6491-6506 Electronic-eCollection
Source:PubMed
PMID: 33995670 doi:10.7150/thno.55821
The PIKfyve Inhibitor Apilimod: A Double-Edged Sword against COVID-19.
Maksim V Baranov, Frans Bianchi, Geert van den Bogaart
Cells. 12 27, 2020.10(1): Electronic
Source:PubMed
PMID: 33375410 doi:10.3390/cells10010030
Synergistic inhibition of two host factors that facilitate entry of Severe Acute Respiratory Syndrome Coronavirus 2
Kreutzberger, A. J. B.; Sanyal, A.; Ojha, R.; Pyle, J.; Vapalahti, O.; Balistreri, G.; Kirchhausen, T.
biorxiv. 2021-06-01. Preprint
Source:biorxiv
PPRID: 10.1101/2021.06.01.446623v1 doi:NA
Synergistic inhibition of two host factors that facilitate entry of Severe Acute Respiratory Syndrome Coronavirus 2
Kreutzberger, A. J. B.; Sanyal, A.; Ojha, R.; Pyle, J.; Vapalahti, O.; Balistreri, G.; Kirchhausen, T.
biorxiv. 2021-06-15. Preprint
Source:biorxiv
PPRID: 10.1101/2021.06.01.446623v2 doi:NA
0